Apixaban and Valve Thrombosis after TAVR

TAVR has been associated with early valve thrombosis, characterized by thrombus formation in the prosthetic valve with or without valve dysfunction. This dysfunction is related to leaflet thickening and reduced motion, reduced effective orifice area, or increased transvalvular gradient. A multidetector CT scan allows the dynamic assessment of valves and ruling out fibrosis vs. thrombosis. 

apixaban en fibrilacion auricular tavi

Subclinical thrombosis by CT is characterized as hypoattenuated leaflet thickening (HALT) and reduced leaflet motion (RLM) which can be identified in up to 10% to 30% of patients. Some studies have linked subclinical valve thrombosis to thromboembolic events. Two registries, the GALILEO (Global Study Comparing a Rivaroxaban-Based Antithrombotic Strategy to an Antiplatelet-Based Strategy After Transcatheter Aortic Valve Replacement to Optimize Clinical Outcomes) and the ATLANTIS (Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischemic and Hemorrhagic Events after Trans-Aortic Valve Replacement for Aortic Stenosis), have suggested the potential use of anticoagulation to prevent subclinical thrombosis. 

The multicenter, randomized study ATLANTIS compared apixaban vs standard treatment after TAVR. The aim of this sub-study ATLANTIS-4D-CT was to assess the incidence of subclinical thrombosis at 90 days, its association to clinical events at 1 year and the effect of treatment. 

Read also: Should We Treat Stroke Percutaneously in TAVR?

Primary end point was the presence of at least one valve with grade III or IV reduced motion, defined as moderate and severe dysfunction (51-70% or >70% motion reduction); and grade III or IV leaflet thickness. Secondary end point was the presence of thrombi in the valve area measured by planimetry, in addition to ischemic events at one year. 

762 patients undergoing 4D CT were looked at; 370 were randomized to Apixaban and 392 to standard treatment. Mean age was 82 and they were mostly women. 

Primary end point occurred in 13% of patients in the standard treatment group vs 8.9% in the Apixaban group. The percentage of patients with marked dysfunction was significantly lower with Apixaban (1.4%) vs. standard treatment (7.1%) (OR: 0.18; 95% CI: 0.07-0.42). The use of Apixaban reduced grade III or IV RLM or HALT by 49% vs. antiplatelet treatment in patients with no indication of anticoagulation (OR: 0.51; 95% CI: 0.30-0.86; P= 0.01), while there were no differences in patients with anticoagulation indication. Neither were there differences in secondary end point. 

Conclusion 

The use of Apixaban as antithrombotic strategy after TAVR reduced valve thrombosis risk in patients with and without long term anticoagulation indication with no increase in thromboembolic or bleeding events. These results must be interpreted with caution given the sub-study design. The use of low doses of Apixaban in low risk populations requires further research. 

Dr. Andrés Rodríguez.
Meber of the Editorial Board of SOLACI.org.

Original Title: Apixaban and Valve Thrombosis After Transcatheter Aortic Valve Replacement The ATLANTIS-4D-CT Randomized Clinical Trial Substudy.

Reference: Gilles Montalescot, MD et al J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...

TAVI and Hypertrophic Cardiomyopathy: An Increasingly Common Association

Stenosis is a common disease affecting 5% of the elderly population. It is associated with hospitalizations, poor quality of life, and mortality.  The association between...

TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients.  The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...